Lauren Ogawa

Dr. Lauren Ogawa

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 January 2025 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Open access
PDF file
IKIshminder Kaur
Ishminder Kaur
BSBennett Shaw
Bennett Shaw
AMAshrit Multani
Ashrit Multani
CPChristine Pham
Christine Pham
SMSanchi Malhotra
Sanchi Malhotra
SYShangxin Yang
Shangxin Yang
Objective: To describe the real-world clinical impact of a commercially available plasma cell-free DNA metagenomic next-generation sequencing assay, the Karius test (KT). Methods: We retrospectively evaluated the clinical impact of KT by clinical panel adjudication. Descriptive statistics were used to study associations of diagnostic indications, host characteristics, and KT-generated microbiologic patterns with the clinical impact of KT. Multivariable logistic regression modeling was used to further characterize predictors of higher positive clinical impact. Results: We evaluated 1000 unique clinical cases of KT from 941 patients between January 1, 2017–August 31, 2023. The cohort included adult (70%) and pediatric (30%) patients. The overall clinical impact of KT was positive in 16%, negative in 2%, and no clinical impact in 82% of the cases. Among adult patients, multivariable logistic regression modeling showed that culture-negative endocarditis (OR 2.3; 95% CI, 1.11–4.53; P .022) and concern for fastidious/zoonotic/vector-borne pathogens (OR 2.1; 95% CI, 1.11–3.76; P .019) were associated with positive clinical impact of KT. Host immunocompromised status was not reliably associated with a positive clinical impact of KT (OR 1.03; 95% CI, 0.83–1.29; P .7806). No significant predictors of KT clinical impact were found in pediatric patients. Microbiologic result pattern was also a significant predictor of impact. Conclusions: Our study highlights that despite the positive clinical impact of KT in select situations, most testing results had no clinical impact. We also confirm diagnostic indications where KT may have the highest yield, thereby generating tools for diagnostic stewardship.

7 December 2024 in Viruses
Verified
Journal Article
Open access
PDF file
LOLauren Ogawa
Lauren Ogawa
CMChelsea Morinishi
Chelsea Morinishi
AMAshrit Multani
Ashrit Multani
PGPryce Gaynor
Pryce Gaynor
OBOmer Beaird
Omer Beaird
JSJoanna Schaenman
Joanna Schaenman
Cytomegalovirus (CMV) infection in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients may increase the risk of rejection or allograft dysfunction, other infection(s), and morbidity and mortality. Treatment can be challenging due to medication-associated toxicities. Maribavir (MBV) is a promising option for the treatment of resistant or refractory (R/R) CMV infection in lieu of foscarnet (FOS), which has long been the recommended therapy for (val)ganciclovir-resistant infection. This was a single-center retrospective study of clinical outcomes of patients who received MBV compared to a control group who received FOS for an episode of CMV infection. Each cohort consisted of 27 episodes of CMV infection. Twenty patients in the MBV cohort and from the FOS cohort cleared the infection, with five and three patients developing MBV or FOS resistance, respectively. There were no statistically significant differences in failure of therapy as evidenced by persistent DNAemia (p = 0.56) or development of antiviral resistance (p = 0.24). In conclusion, MBV was as effective as FOS for the treatment of R/R CMV infection and was better tolerated without increased risk of antiviral resistance.

22 August 2024 in Transplantation Proceedings
Verified
Journal Article
Closed access
LOLauren Ogawa
Lauren Ogawa
AMAshrit Multani
Ashrit Multani
OBOmer E. Beaird
Omer E. Beaird
PGPryce Gaynor
Pryce Gaynor
MCMargrit Carlson
Margrit Carlson
JSJoanna M. Schaenman
Joanna M. Schaenman

8 June 2019
Verified
Conference Paper
Closed access
LOLauren Ogawa
Lauren Ogawa
NSNishkarsh Saxena
Nishkarsh Saxena
MLMercury Lin
Mercury Lin

4 August 2026 in Reviews in Medical Virology
Verified
Journal Article
Closed access
PDF file
SCSorawit Chittrakarn
Sorawit Chittrakarn
PKPornpan Koomanachai
Pornpan Koomanachai
KSKamonlawat Sutthipool
Kamonlawat Sutthipool
LOLauren Ogawa
Lauren Ogawa
JSJoanna Schaenman
Joanna Schaenman